ABSTRACT
We report a rare case of pleomorphic carcinoma of the breast, suspected of being a granulocyte-colony stimulating factor (G-CSF)producing tumor, in a 75-year-old woman. She presented with a red and swollen breast, 3 weeks after undergoing core needle biopsy(CNB). Her leukocyte counts and C-reactive protein(CRP)levels were markedly high. At first, she was suspected to have an abscess and was initiated on a course of antibiotics. However, her condition rapidly deteriorated; therefore, she underwent an emergency mastectomy. Despite undergoing postoperative radiation therapy, 2 months after the operation, multiple metastatic foci were found in the lungs and liver, and she died of the disease 3 months after her first visit. After the operation, her leukocyte count had quickly returned to normal, but it increased as the disease progressed. These findings support the conclusion that this carcinoma was producing G-CSF. The final pathological diagnosis was G-CSF producing pleomorphic carcinoma of the breast.
Subject(s)
Adenoma, Pleomorphic/metabolism , Granulocyte Colony-Stimulating Factor/biosynthesis , Inflammatory Breast Neoplasms/metabolism , Inflammatory Breast Neoplasms/pathology , Aged , Disease Progression , Female , Humans , Inflammatory Breast Neoplasms/diagnosisABSTRACT
We report a 55-year-old female with liver metastases from breast cancer who responded to lapatinib and capecitabine combination therapy as third-line. She was diagnosed as invasive ductal carcinoma (T1cN1M0, stage IIA). Biomarker of breast cancer was negative hormone receptor (ER-, PgR-) and overexpression of HER2(HercepTest 3+). We started preoperative chemotherapy with weekly paclitaxel followed by FEC100. Then mastectomy with axillary dissection was performed. Histopathology of the breast and lymph nodes showed complete disappear of invasive cancer cells( pCR, grade 3). We performed her adjuvant therapy with trastuzumab after surgery. The liver metastases developed 5 months after surgery. We treated her in trasutumab combined with vinorelbine, and followed by docetaxel during one year and four months. Because liver metastases re-grew during the combination therapy with trastuzumab, we switched to lapatinib and capecitabine combination therapy. After four months of administration, abdominal CT revealed liver metastases were remarkably reduced in size. The efficacy of chemotherapy lasted for eight months.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Carcinoma, Ductal, Breast/drug therapy , Deoxycytidine/analogs & derivatives , Fluorouracil/analogs & derivatives , Liver Neoplasms/drug therapy , Quinazolines/therapeutic use , Breast Neoplasms/pathology , Capecitabine , Carcinoma, Ductal, Breast/pathology , Deoxycytidine/administration & dosage , Deoxycytidine/therapeutic use , Fatal Outcome , Female , Fluorouracil/administration & dosage , Fluorouracil/therapeutic use , Humans , Lapatinib , Liver Neoplasms/secondary , Middle Aged , Quinazolines/administration & dosageABSTRACT
A recent breast cancer operation appears to have become more simplified, and we may cure an early stage breast cancer without a surgery in the future. This study was approved by our institutional review board and all patients received the study information. We started a radiofrequency ablation (RFA) in April 2008 for breast cancer patients without extensive ductal spreads and the tumor size of 2 cm or less measured by magnetic resonance imaging (MRI). At first, we performed five patients from a clinical viewpoint of technique and safety. All cases were performed safely. There was no complication such as burns. At the mid observation period of 22 months in average (range 21-24), no local recurrence and distant metastases were occurred after RFA. Cosmetic after RFA was excellent in all cases.
